Reversing novel oral anticoagulant: new agent available – Certificate of Completion

On completion of this program, participants will be better able to:

• Review the mechanism of actions, indications, contra-indications, advantages and disadvantages of direct acting anticoagulants (DOACs), with a focus on dabigatran
• Evaluate the evidence supporting the use of idarucizumab to reverse the anticoagulant effects of dabigatran
• Recall the indications and practical issues associated with administration of idarucizumab